Signal2026-05-14
ClinicalTrials.gov

[PHASE2] Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Part of

Prostate Cancer Biomarker And Treatment Research

Open primary sourceSee the whole picture